Integral Derivatives’s Allergan plc AGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q1
$1.13M Sell
6,700
-14,500
-68% -$2.43M 0.03% 209
2017
Q4
$3.47M Sell
21,200
-24,300
-53% -$4.36M 0.07% 187
2017
Q3
$9.32M Sell
45,500
-8,700
-16% -$2.02M 0.17% 69
2017
Q2
$13.2M Buy
54,200
+41,900
+341% +$9.85M 0.27% 41
2017
Q1
$2.94M Sell
12,300
-45,100
-79% -$10.5M 0.05% 228
2016
Q4
$12.1M Buy
57,400
+21,800
+61% +$4.52M 0.22% 52
2016
Q3
$8.2M Sell
35,600
-33,700
-49% -$8.24M 0.17% 77
2016
Q2
$16M Buy
69,300
+37,800
+120% +$8.72M 0.39% 29
2016
Q1
$8.44M Sell
31,500
-16,800
-35% -$4.81M 0.28% 55
2015
Q4
$15.1M Buy
48,300
+21,600
+81% +$6.43M 0.38% 37
2015
Q3
$7.26M Buy
26,700
+7,900
+42% +$2.43M 0.2% 73
2015
Q2
$5.71M Sell
18,800
-16,500
-47% -$4.92M 0.16% 107
2015
Q1
$10.5M Buy
35,300
+17,600
+99% +$5.02M 0.22% 53
2014
Q4
$4.56M Buy
17,700
+1,200
+7% +$300K 0.08% 216
2014
Q3
$3.98M Buy
16,500
+6,700
+68% +$1.5M 0.07% 248
2014
Q2
$2.19M Sell
9,800
-9,500
-49% -$1.97M 0.04% 388
2014
Q1
$3.97M Buy
19,300
+14,300
+286% +$2.83M 0.08% 223
2013
Q4
$840K Buy
+5,000
New +$782K 0.01% 852

Other funds holding AGN

Integral Derivatives's AGN Position: Q4 2017 in Review

Integral Derivatives sold out of Allergan plc (AGN) in Q4 2017, closing a stake of 12,594 shares — an estimated $2.26M sold.

Integral Derivatives first reported a position in AGN in Q4 2013 and held it in 15 quarters. The position peaked at $8.62M in Q4 2016. 1,048 funds tracked by Wall St. Rank hold AGN as of Q4 2017.

  • Integral Derivatives reported no remaining Allergan plc position as of Q4 2017 after selling out during the quarter.
  • Integral Derivatives sold 12,594 Allergan plc shares in Q4 2017, an estimated $2.26M.
  • Integral Derivatives first reported a position in Allergan plc in Q4 2013 and held it in 15 quarters.
  • Integral Derivatives's Allergan plc position peaked at $8.62M in Q4 2016.
  • 1,048 funds tracked by Wall St. Rank held Allergan plc as of Q4 2017.

Based on Integral Derivatives's 13F filing for Q4 2017, filed 14 Feb 2018.